Key Takeaways
- Enodia Therapeutics has acquired Kezar Life Sciences’ Sec61-based discovery program for $1 million.
- The agreement could yield up to $127 million through milestone payments and tiered royalties.
- This acquisition will enhance Enodia’s research into Sec61 selectivity, expediting clinical progress.
Acquisition Details
On March 12, 2026, Enodia Therapeutics, a biotechnology firm focusing on small-molecule therapies for targeted protein degradation, announced its acquisition of Kezar Life Sciences’ assets related to its Sec61-based discovery and development program. The agreement entails an initial upfront payment of $1 million, with potential additional payments up to $127 million, contingent on various development, regulatory, and commercialization milestones.
In addition to the upfront payment, Enodia will provide tiered royalties on net sales derived from the acquired assets. The acquisition is poised to deepen Enodia’s understanding of Sec61 selectivity mechanisms, facilitating faster development toward critical clinical milestones.
Wilson Sonsini Goodrich & Rosati provided legal advice to Enodia throughout the transaction, with a team consisting of Seth Flaum, Aleksandar Vitomirov, and Greg Broome.
For further details, a comprehensive press release is available on Enodia’s website, with additional insights featured in Fierce Biotech.
The content above is a summary. For more details, see the source article.